| 5.22 -0.23 (-4.22%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.49 | 1-year : | 8.75 |
| Resists | First : | 6.42 | Second : | 7.49 |
| Pivot price | 4.2  |
|||
| Supports | First : | 4.13 | Second : | 2.71 |
| MAs | MA(5) : | 5.34 |
MA(20) : | 3.98 |
| MA(100) : | 3.74 |
MA(250) : | 3.33 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 72.2 |
D(3) : | 71.9 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 6.42 | Low : | 1.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LRMR ] has closed below upper band by 28.8%. Bollinger Bands are 303.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.56 - 5.59 | 5.59 - 5.62 |
| Low: | 5.1 - 5.13 | 5.13 - 5.17 |
| Close: | 5.16 - 5.22 | 5.22 - 5.28 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Wed, 04 Mar 2026
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
Tue, 03 Mar 2026
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00 - MarketBeat
Tue, 03 Mar 2026
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative
Mon, 02 Mar 2026
Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com
Mon, 02 Mar 2026
Insider Buying: Frank Thomas Acquires Additional Shares of Larimar Therapeutics Inc (LRMR) - GuruFocus
Sat, 28 Feb 2026
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 83 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 88 (%) |
| Shares Short | 8,770 (K) |
| Shares Short P.Month | 8,240 (K) |
| EPS | -1.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43 % |
| Return on Equity (ttm) | -78.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -96 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | 0 |
| Price to Book value | 3.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|